Abstract | The bone marrow niche consists of stem and progenitor cells destined to become mature cells such as haematopoietic elements, osteoblasts or adipocytes. Marrow cells, influenced by endocrine, paracrine and autocrine factors, ultimately function as a unit to regulate bone remodelling and haematopoiesis. Current evidence highlights that the bone marrow niche is not merely an anatomic compartment; rather, it integrates the physiology of two distinct organ systems, the skeleton and the marrow. The niche has a hypoxic microenvironment that maintains quiescent haematopoietic stem cells (HSCs) and supports glycolytic metabolism. In response to biochemical cues and under the influence of neural, hormonal, and biochemical factors, marrow stromal elements, such as mesenchymal stromal cells (MSCs), differentiate into mature, functioning cells. However, disruption of the niche can affect cellular differentiation, resulting in disorders ranging from osteoporosis to malignancy. In this Review, we propose that the niche reflects the vitality of two tissues -bone and blood -by providing a unique environment for stem and stromal cells to flourish while simultaneously preventing disproportionate proliferation, malignant transformation or loss of the multipotent progenitors required for healing, functional immunity and growth throughout an organism's lifetime. Through a fuller understanding of the complexity of the niche in physiologic and pathologic states, the successful development of more-effective therapeutic approaches to target the niche and its cellular components for the treatment of rheumatic, endocrine, neoplastic and metabolic diseases becomes achievable.
Bone marrow is a remarkable multifunctional tissue that contains stem, progenitor and mature cells of several lineages. Stem cells have, by definition, the capacity to self-renew and differentiate into many different types of cells 1 (FIG. 1) . Haematopoietic stem cells (HSCs) are multipotent cells that differentiate into myeloid, lymphoid and erythroid lineages, and have short-term or long-term regenerative capacity. By contrast, bone marrow cells of purely mesenchymal origin -that is, mesenchymal stromal cells (MSCs) -considered within a strict definition based on cell-surface markers and function (TABLE 1) , include cells capable of tissue culture plastic adherence and expansion but exclude the non-stromal elements of the marrow such as osteoclasts, macrophages, and endothelial cells 2 . The bone marrow 'stem cell niche' refers to the unique microenvironment of these regenerative cells in the bone marrow. This niche forms an anatomical and functional unit of physiology that integrates endocrine, autocrine, and paracrine signalling to serve the needs of the whole organism by sustaining the stem cell pool 3 .
Mobilization and export of HSCs from the bone marrow can occur with injury, acute inflammation or biochemical stress, or during tissue repair. The stem cell pool that remains in the bone marrow after stress-induced haematopoiesis is essential for its repopulation and revitalization. In this Review, we summarize the unique physiological aspects of the bone marrow niche and the consequences of its alteration. In addition, we examine this microenvironment as it relates to cancer cells that invade and hijack the function of the niche [4] [5] [6] .
Function and anatomy of the niche

Functional aspects
The bone marrow niche has several functions including the production of blood-forming elements, the maintenance of HSCs, and the modulation of skeletal remodelling. HSCs have the unique capacity to give rise to all mature blood cell types and are self-renewing; that is, during asymmetric division a proportion of the daughter cells remain HSCs, such that the pool of these cells is not depleted. Within the HSC pool are transient self-renewing HSCs and long-term quiescent HSCs. By contrast, bone marrow MSCs that regulate bone remodelling are multipotent, self-renewing progenitor cells that can differentiate into other cell types (for example, osteoblasts, adipocytes or chondrocytes) 7 . HSC quiescence is strongly dependent on MSCs and MSC-descendants, illustrating an important role for MSCs in the bone marrow niche 8 . The delicate balance between HSCs and MSCs provides a critical integration point between the marrow and the skeleton. In physiologic states, as well as in injury and chronic diseases, several types of progenitor cells are required to perform specific functions beyond bone remodelling and maintenance of haematopoiesis. Importantly, roles for the niche in modulating tumour biology and immunity have also emerged, further enhancing its importance but also emphasizing its complexity.
Location and organization
Defining the physical location of the bone marrow niche can be challenging because of considerable interindividual and inter-species differences in the bone marrow. Classically, the principal bone marrow niche component is that which supports the cells that ultimately defines haematopoiesis; that is, HSCs, which are destined for differentiation and subsequent export into the circulation 9 . Today the bone marrow niche is reconsidered within the functional context of MSCs, which are essential for maintaining a stable pool of osteoblast progenitors for bone remodelling 10, 11 . Human and rodent MSCs have been used experimentally as therapeutic tools to hasten fracture repair or injury recovery in many tissues 11, 12 . Enhanced MSC differentiation into osteogenic lineage cells has been directly linked to the maintenance of HSCs in their quiescent state 13 . Still, the balance between quiescence, self-renewal, and differentiation of HSCs in the bone marrow niche is dynamic, and modulated in part by MSCs. Hence, what has emerged is a new concept of dual
Key points
• The bone marrow niche supports the integration of two major organ systems -the skeleton and the marrow • The niche is a unique microenvironment that is crucial for haematopoietic stem cell quiescence • Important features of the niche include its cellular components, hypoxia, extracellular matrices, cytokines and growth factors, and vascularization • Multiple myeloma and other cancer cells hijack and alter the bone marrow niche, and are altered by the niche in turn; thus, targeting niche-cancer interactions is a promising therapeutic avenue • Novel in vitro and in vivo models of the bone marrow niche and cancer cells enable us to better understand interactions between cancer and bone marrow niche cells • A more complete understanding of the biology of the unique bone marrow microenvironment must remain a major research priority stem cell populations that share a common location, with an interdependent relationship of both mutual support and competition for the marrow space 14 . Anatomically, the niche is more than a series of HSCs clinging to MSCs and osteoprogenitors within a flat marrow space. Rather, it is a 3D structure adjacent to the perivascular (or sinusoidal) space created by endothelial cells, in close proximity to trabecular bone and other cells 15, 16 . In addition to those components, the niche also has matrix elements and microvessels that probably have regulatory capacities, particularly with respect to the unique biochemical composition of the milieu (see later). In that vein, the niche can be considered as two mini organ systems interacting at a single site that has specific environmental characteristics 17 (FIG. 2) .
Notwithstanding this concept, reconciling the role of trabecular bone with haematopoiesis remains a challenge. However, the identification by Bianco, Robey and others of the cellular phenotype of multipotent MSCs (CD146 + adventitial cells adjacent to sinusoids) and emerging evidence of the role of bone lining cells has allowed for a more-complete understanding of the organization of the haematopoietic niche, and the importance of MSCs and the endosteal surface of trabecular bone to the production of differentiated marrow elements 7, 18, 19 .
Cellular components
As well as HSCs and MSCs, several other cellular components of the bone marrow have been recognized as critical for the maintenance of a healthy niche. The aforementioned cells include bone lining cells, osteo blasts, marrow adipocytes, resident tissue macrophages ('osteomacs'), immune cells, canopy cells, and neurons, which are discussed respectively in this section; features of the main cellular components of the bone marrow niche are summarized in TABLE 1. These cells are simultaneously reliant on the niche and essential for its function.
Bone lining cells on the endosteal surface that express transcription factor Sp7 (also known as osterix) are precursors to osteoblasts and osteocytes 20 . These cells have been difficult to characterize but generally are flat and fibroblastic in appearance. They could have an important role in replacing bone-forming cells during physiologic remodelling and in response to anabolic therapies such as parathyroid hormone (PTH) 21 . Whether these cells can also differentiate into adipocytes remains to be proven but raises the interesting concept of a secondary pool of multipotent MSCs within the niche proper.
Osteoblasts are critical regulators of HSC fate within the bone marrow niche 22 . These cells are in close proximity to HSCs; moreover, regulatory factors that enhance MSC differentiation into the osteoblastic lineage can also promote the development of the bone marrow niche as well as the expansion and egress of HSCs 23 . The Kronenberg group was one of the first to establish the importance of osteoblasts in maintaining HSCs within the niche 13 . The same group also showed that recombinant PTH stimulated expansion and egress of HSCs, and that constitutive upregulation of the PTH-PTH-related peptide (PTHrP) receptor in osteoblasts disrupted normal haematopoiesis 24 . Ten years later, Coskun and colleagues showed that lack of Sp7 in osteoblast-lineage cells allowed for vascularization of developing bone marrow, but HSC proliferation and differentiation potential were considerably impaired 25 . In addition, Omatsu et al. 26 reported that expression of the transcription factor FoxC1 in osteoprogenitor and CXCL12-abundant reticular (CAR) cells was essential for maintenance of haematopoietic stem and progenitor cells in vivo. Thus, MSCs, osteoblasts and their progenitors are essential components for niche homeostasis.
Marrow adipocytes, which reside close to the endosteal surface, were long considered 'filler' for the marrow compartment. This notion was based on ana tomical studies of marrow from patients with age-related osteoporosis, aplastic anaemia, myelodysplasia, and after radiation or chemotherapy 27 , in which adipocytes were abundant within fibrotic or empty marrow spaces 28, 29 . However, work in the past 3 years has demonstrated a much more complicated role for the adipocyte within the bone marrow niche 30 . For example, there are probably two major types of marrow adipose tissue (MAT): one that is found in the distal tibia and tail of rodents and which is formed shortly after birth (constitutive MAT), and one that is noted later in life in the proximal femur and verte brae in close proximity 32 . With regard to the skeleton, constitutive MAT volume, as measured by use of osmium staining and microCT in rodents and MRI in humans, is inversely related to bone mass 33, 34 . By contrast, regulated MAT seems to be a more dynamic adipose tissue that has endocrine and paracrine effects on both the haemato poietic and skeletal remodelling systems 35 . A high volume of regulated MAT is often, although not always, associated with low bone mass 36, 37 . Osteomacs (bone-marrow-resident macrophages; F4/80 + in mice, CD68 + in humans) are also pivotal to the maintenance of the endosteal bone marrow niche 38 . Osteomacs facilitate the homing to bone, colonization, and dormancy of HSCs, and loss of osteomacs leads to the egress of HSCs into the blood 39 . Osteomacs are distributed throughout the endosteum and periosteum and are vital to MSC osteogenic differentiation in vivo and in vitro 38, 40 , potentially contributing to the canopy covering the bone remodelling canopy (discussed later) in bone modelling sites 41 . Winkler et al. 39 suggest that osteomacs might also maintain 42 . These innate immune cells are stress-responsive and, thus, can communicate with other cells within the niche to regulate HSC egress. In essence, the presence of this immunomodulatory network establishes a permissive environment that could enable colonization by foreign cells. This is sometimes referred to as 'bone-specific immunity' , as the niche is an immune-privileged environment 43 . The consequences of this specialized milieu are evident clinically in the frequent occurrence of tumour metastases in bone (discussed later), as well as serious infections such as tuberculosis involving this tissue before widespread dissemination 44 . A 'canopy' or cellular membrane has been described that covers not only cuboidal osteoblasts in the periosteum but also the bone remodelling unit 45, 46 . This canopy might serve several functions beyond the insulation of bone cells from external stimuli or invasion. It might also be an important part of the niche, as it is composed of flattened cells and microvessels that provide nutrients and substrates for cells contained within that space, including MSCs, bone lining cells, osteoblasts, osteoclasts, and osteocytes 45, 46 . The precise relationship between the canopy and the niche has not been determined, in part because of the difficulty in defining both their anatomic locations and the lack of functional tools to trace canopy cell activity.
Three other key cell types that contribute to the niche are endothelial cells, pericytes and megakaryocytes. Megakaryocytes contribute profoundly to the niche by supporting HSC quiescence through production of platelet factor 4 (also known as CXCL4) and transforming growth factor (TGF)-β 47, 48 . Sinusoidal endothelial cells, through expression of E-selectin 49 , stromal cell-derived factor (SDF1, also known as CXCL12 (REF. 50)) and vascular endothelial growth factor (VEGF) receptor 2 (REF. 51 ), are critical for HSC maintenance and haematopoietic recovery from myeloablation. Importantly, peri cytes, which enwrap endothelial cells of vessels, were found to be necessary for HSC homeostasis primarily through expression of stem cell factor by perivascular cells throughout the bone marrow 52 . Finally, neural regulation of the niche and control of HSC export is mediated primarily through the sympathetic nervous system (SNS). The cyclic release of HSCs and expression of SDF1 and its receptor, CXCR4, are regulated by molecular clock genes, mediated by circadian secretion of noradrenaline from sympathetic nerves 53 . These adrenergic signals are delivered locally by nerves in the bone marrow and transmitted to MSCs through β3-adrenoceptors. Moreover, MSCs express α1B, α2A, and β2-adrenoceptors that make them responsive to noradrenaline and other signals that promote changes in their metabolic requirements 54 . Activation of the SNS leads to the rapid downregulation of CXCL12 expression and the export of HSCs and other types of immune cells into the circulation. β2-adrenoceptors on MSCs can mediate changes in osteoblast differentiation and, ultimately, bone remodelling 54 .
Biochemistry of the niche
The bone marrow niche has its own unique biochemistry, supported by a rich vasculature that makes it particularly suitable for stem cells. The endosteal surface of each trabecula is surrounded by bone marrow with constituent progenitor and stem cell populations. The endosteum also contains pre-osteoblastic cadherin-2-expressing cells, and has nerve and blood supplies 55 , although these features are difficult to detect with plain-light microscopy. The heterogeneous environment of the endosteum contains scattered regions of microvascular infiltration, and other regions of relative hypoxia 56 that are highly attractive regions for HSC-homing [57] [58] [59] . Interestingly, quiescent HSCs tend to reside in areas of very low blood perfusion, whereas more proliferative HSCs with a lower reconstitution potential tend to prefer areas with greater blood flow 59 . The hypoxic microenviron ment in the endosteum is a major factor in the integration of skeletal and haematopoietic functions, owing in part to the central role of hypoxia-inducible factor (HIF)-1α in HSC differentiation 60, 61 .
Metabolic reprogramming in hypoxia
Hypoxia induces a cellular response via a family of HIFs expressed in HSCs and MSCs that regulate a number of downstream signals. HIF transcription factors are composed of one of three oxygen-sensitive α-subunits -HIF-1α, HIF-2α or HIF-3α -and a constitutively expressed β-subunit, HIF-1β, also called aryl hydrocarbon receptor nuclear translocator (ARNT) 57 . Once the HIF-α subunit binds ARNT, the binary complex translocates to the nucleus and activates the transcription of genes containing hypoxia-responsive elements (HREs) 59 . In normal oxygen conditions, or when O 2 concentration exceeds 5%, HIF-1α protein is degraded by the proteasome within 5 min 62, 63 . Three prolyl hydroxylase domain (PHD) enzymes hydroxylate two residues within the oxygen-degradation domain of HIF-1α, leading to ubiquitination and subsequent degradation of the HIF complex 62 (FIG. 3) .
Pharmacologic approaches to inhibit PHD proteins and stabilize HIF-1α are currently in clinical trials for the treatment of anaemia caused by chronic kidney disease and to enhance stem cell pools after chemotherapy and radiation therapy 58 . Survival and maintenance of HSC 'stemness' in hypoxia requires substantial metabolic adaptations. As noted above, relative hypoxia (in which O 2 concentration may be as high as 5%) induces the stabilization of HIF-1α in HSCs as well as the transcription of multiple downstream target genes including VEGFA 64 . Metabolic reprogramming of quiescent cells is necessary to prevent differentiation, and this reprogramming occurs through a shift from oxidative phosphorylation to glycolysis 65, 66 . Importantly, glycolysis, although less efficient than mitochondrial oxidation in generating ATP, reduces oxidative stress and generation reactive oxygen species (ROS), both of which drive stem cell differentiation. Indeed, HSCs are particularly well-suited to tolerate oxidative stress through a well-organized antioxidant defence system. The hypoxic environment of the niche leads to changes in substrate utilization in order to fuel cellular activity. Hypoxia induces ATM kinase (ATMK), which catalyses hypoxia inducible factor-1α (HIF-1α) activity. HIF-1α is stabilized by binding to aryl hydrocarbon receptor nuclear translocator (ARNT); the HIF-1α complex enters the nucleus and regulates a number of genes, particularly those related to glycolysis. Consequently, glucose is utilized for ATP generation through lactate production and via the pentose phosphate shunt for nucleotide synthesis that is essential for cell proliferation. Alternatively, and particularly during normoxia, HIF-1α is rapidly broken down in the proteasome via ubiquitination by proline hydroxylase domain (PHD) enzymes. G6P, glucose-6-phosphate; GLUT1, glucose transporter 1; LDH-A, lactate dehydrogenase A; PEP, phosphoenolpyruvate; PK, protein kinase; R5P, ribose-5-phosphate; TCA, tricarboxylic acid; VHL, von Hippel-Lindau tumor suppressor.
MSCs also express HIF proteins and respond to hypoxia similarly to HSCs, with the upregulation of multiple HIF-inducible genes following translocation of the transcription factor complex to the nucleus 63 . Enhanced HIF-1α protein expression promotes osteo genic differentiation over adipogenesis in the marrow 67 , potentially via increased production of VEGF-A, which is a potent angio genic factor, and its subsequent suppression of peroxisome proliferator-activated receptor γ (PPAR-γ). VEGF-A has been shown to be essential for endochondral bone formation in vivo, and for MSC differentiation into osteo blasts through binding to VEGF receptor 2 (REF. 68 ). Other HIF-inducible proteins in MSCs include lactate dehydrog enase A (LDH-A), phospho glycerate kinase and glucose transporter 1 (GLUT1), all of which are essential for the promotion of glycolysis over oxidative phosphorylation and, ultimately, for osteogenic differentiation 67, 69 . Two key proteins, GLUT1 and LDH-A, are both upregulated during hypoxic conditions in HSCs and MSCs via activation of the transcription factor HIF-1α. As noted, mitochondrial respiration must be suppressed to enable glycolysis to predominate; this suppression occurs through the hyperactivation of AMP kinase (AMPK) and downregulation of several relevant mitochondrial genes, as well as the suppression of ROS production. Activation of AMPK by metformin, an anti-diabetes drug, enhances glycolysis, but also suppresses HSC differentiation and maintains the stemness of these cells 65, 70 . By contrast, metformin has been shown to enhance MSC differentiation, also through AMPK, by upregulating the master osteogenic transcription factor RUNX2 (REF. 71 ). Studies from independent laboratories have confirmed that osteogenic differentiation is driven almost exclusively by glycolysis and that GLUT1 is essential to that process 72, 73 . Moreover, PTH, which can enhance HSC egress and MSC differentiation, works by inducing glycolysis in differentiated osteoblasts, probably through upregulation of GLUT1 and GLUT3 expression 74 . Overall, it is clear that the bioenergetics of cells in the niche, driven by ATP demand, help determine how specific transcriptional factors induce the differentiation of stem and progenitor cells.
Effects of growth factors
Biochemical changes in both HSCs and MSCs also occur as a result of vascular and paracrine delivery of cytokines and chemokines. For example, HSC mobilization occurs because of key receptor-ligand interactions, particularly SDF1-CXCR4 (REF. 75 ). Other ligands and their receptors are also integrated within the bone marrow niche, including integrin α-4-VCAM1 (vascular cell adhesion protein 1), L-selectin (CD62L)-PSGL-1 (P-selectin glycoprotein ligand 1, or CD162) hyaluronic acid (HA)-CD44, and mast/stem cell growth factor receptor Kit (c-Kit, or CD117)-Kit ligand 76 . Ephrin type-B receptor 4 (EPHB4) is a tyrosine kinase receptor that has been shown to modulate HSC fate through its ligand ephrin-B2 (REF. 77 ). In sum, it is apparent that growth factors signal the egress of HSCs from the marrow and also probably encourage the use of alternative metabolic pathways to support differentiative function or, in some cases, to inexorably alter stem cell fate.
Consequences of niche disruption
The intricate balance between HSCs and MSCs is subject to disruption by many factors, including tumour-cell invasion, excessive ROS production, substrate insufficiency and a host of drugs used to treat autoimmune diseases that might unintentionally harm the niche. Pathologic changes in MSC differentiation can also alter the niche and lead to activation of tumorigenesis via the Notch signalling pathway. For example, in a 2014 study, Krevvata et al. 78 demonstrated that constitutive activation of β-catenin interacts with Foxo1 in osteoblasts and MSCs, which in turn enhances the expression of the Notch ligand protein jagged-1. In long-term repopulating HSCs, chronic exposure to jagged-1 results in leukaemic transformation 79 .
Cancer-related disruption of the niche Niche colonization by tumour cells The unique properties of the bone marrow niche make it exceptionally conducive to colonization by tumour cells (FIG. 4) : the niche can be considered as 'fertile soil' for malignant cell 'seeds' . Breast cancer, prostate cancer and multiple myeloma cells strongly prefer to metastasize and grow within the bone marrow rather than other anatomical locations, not only because of its characteristic properties described above, but also due to positive-feedback loops initiated by tumour cells within the niche. By causing osteolytic (bone-destructive, common in breast cancer and multiple myeloma) or osteoblastic (bone-forming, common in prostate cancer) lesions, cellu lar crosstalk is initiated that supports tumour growth and uncoupling of bone remodelling. As reviewed elsewhere, osteolytic cancers induce a forward-feedback loop termed the 'vicious cycle' , in which bone-embedded growth factors, extracellular matrix proteins, and calcium are released as bone is resorbed, which then signal to tumour cells, accelerating their proliferation 80, 81 . When receptor activator of NFκB (RANK) on pre-osteoclasts is stimulated by RANK ligand (RANKL), produced by osteoblasts and tumour cells, osteoclast number and activity are increased, which directly supports multiple myeloma cells 82 . Osteoclastogenesis then leads to bone degradation via resorption pits and proteinases, such as cat hepsin K, which can also be produced by tumour cells 83 . RANKL itself has also been identified as a tumour chemokine 84 , creating an intricate web of signalling interactions between osteoblasts, osteoclasts, and tumour cells.
As tumour cells take hold and begin to grow in the favourable conditions of the bone marrow, they modulate and usurp the marrow to support their own growth at the expense of normal bone homeostasis, leading to increased fractures, hypercalcaemia, spinal cord compression, immune cell dysfunction, pain, and, eventually, death 85 . The microenvironment not only is required for this process, but also changes in response to tumour growth. For example, MSCs from patients with multi ple myeloma and myelodysplastic syndrome are abnormal due to the effects of local tumour cells, and have inhibi ted osteogenesis and increased tumour-supportive functions, which are driven through numerous mech anisms [86] [87] [88] . Similarly, leukaemic myeloid cells also hijack the normal osteogenic process by stimulating MSCs to overproduce functionally altered osteoblast-lineage cells, which accumulate in the bone marrow cavity as inflammatory myelofibrotic cells 89 . These myeloproliferative neoplasia-associated osteoblasts, in turn, exhibit decreased expression of many HSC-retention factors and have a severely compromised ability to maintain normal HSCs, but are more efficient at harbouring leukaemia stem cells 89 . Targeting this pathological inter play between osteoprogenitor-lineage cells and tumour cells represents a key avenue to treat myeloproliferative disease or bone metastasis. Hence, the 'fertile soil' of the bone marrow is not only responsible for the successful growth of tumour cell 'seeds' , but is also, by the same metaphor, fertilized further by the tumour cells themselves, as they create a more hospitable environment for further tumour colonization and expansion.
Facilitating tumour survival
The bone marrow also provides protection from anticancer therapies through cell adhesion-mediated drug resistance (CAM-DR). This resistance is, in part, due to the quiescent state induced in cells within the bone marrow niche, which allows for long-term survival of malignant cells. The ability of the bone marrow niche to revert cells to a stem-cell state can cause tumour cells that are no longer clonogenic to revert to a stem-like state after signalling from the bone marrow via myofibroblast-derived factors such as hepato cyte growth factor 90 . Thus, cancer cell stemness is not a fixed state, but can be instilled and nurtured by the niche. The niche also provides numerous growth factors that facilitate tumour quiescence or growth; precisely what dictates tumour cell fate (that is, apoptosis, dormancy, self-renewal, or proliferation) is still unclear 91 . Importantly, the plasticity of differentiation that is characteristic of putative cancer stem cells (CSCs), which can be driven by bone marrow interactions, suggests that eradicating CSCs would not stop tumour growth as more CSCs could be reinitiated from dedifferentiation of non-stem cells upon association with the niche 92 . Although evidence for this mechanism is clear with leukaemia-initiating stem cells 90 , the presence of stem cells or tumour-initiating cells remains controversial in other cancers, such as multiple myeloma, and hence the role of the bone marrow is likely to be dependent on tumour type and clonal properties.
Many molecules, including matrix metalloproteinases, VEGFs, activin-A, and connective tissue growth factor, facilitate tumour survival in the bone marrow and can act as cell-nonautonomous factors 93, 94 . Bone-derived factors such as the TGF-β family cytokines and insulin-like growth factors stimulate tumours to activate osteoblasts via molecules such as VEGF, platelet derived growth factor (PDGF), and endothelin-1 (REFS 94, 95) . TGF-β (through Smad pathway signalling), hypoxia (through HIF-1α), and extracellular calcium (through protein kinase B (PKB) and MAPK pathways) alter gene expression within tumour cells in the bone micro environment, enabling the survival and growth of these cells in the marrow cavity 94, 96, 97 . Many osteo lytic tumour cells produce PTHrP, TGF-β, dickkopf-1, sclerostin, and RANKL; moreover, osteo blastic tumours often secrete bone morphogenic proteins and other growth factors (such as fibroblast growth factors and Wnt family members), but many of the mechanisms of osteo blastic lesion development remain undetermined 98 . Metabolic changes in tumour cells induced by their local micro environment are also now recognized as important contributors to tumour growth and potential therapeutic targets 99 .
Effects of bone marrow cells on tumours
The many cells that contribute to the 'fertile soil' of the niche have been reviewed previously and described above 81, 100, 101 . Just as these cellular elements of the bone marrow are important in supporting and regulating the haematopoietic niche, they also have roles in the promotion, and perhaps the inhibition, of tumours within the bone marrow. For example, myeloid-lineage progen itor cells (CD11b + ), have been shown to support tumour growth, migration, and invasion in vitro and, when co-implanted with tumour cells, can promote metastasis in vivo 102 . Macrophages also are important in supporting multiple myeloma, other haematological malignancies, and metastatic tumours through contact-mediated and non-contact-mediated mechanisms 103 , while the effect of bone marrow adiposity on tumour niche colonization is a new frontier in cancer research.
Osteoblasts are decidedly vital in maintaining HSC quiescence, but their putative effects on tumour cells are more controversial and include inducing dormancy, cell-cycle arrest, apoptosis, or proliferation, depending on the models, osteoblast cells, culture conditions and tumour cells used 88 . Osteoblasts might also have an anti-leukaemic role 104 , and osteoblast numbers are significantly deceased in leukaemia 78 . Our review published in early 2015 discussed the roles of endosteal osteo blasts and bone marrow adipocytes in myeloma 88 and others have reviewed this topic for breast and prostate cancers 105 . The newly appreciated roles of osteocyte signalling, specifically the osteocyte-derived Wnt-inhibitor sclerostin, from lacunae to healthy and cancerous bone marrow niches, has also been reviewed in a 2014 publication 106 . Targeted reprogramming of interactions between bone marrow cells and tumour cells could prove to be a breakthrough in therapeutic approaches to inhibiting tumour growth in bone.
Within the bone marrow, MSCs have been shown to support tumorigenesis in a plethora of ways, for example by inducing angiogenesis and via secreted chemokine and contact-mediated paracrine signalling. MSCs can support growth, increased aggressiveness, and self-renewal of multiple myeloma, leukaemia, and other solid tumours in vitro and in vivo through the activation of pathways such as PKB, Ras, NFκB, HIF-1α, Myc, human telomerase reverse transcriptase and interferon regulatory factor 107 , and by creating specific CSC niches through cytokine loops involving IL-6 and platelet basic protein (CXCL7) 108 . Myeloma-associated MSCs are distinct with regards to gene expression, function, proliferation and differentiation potential from MSCs from healthy donors, representing one example of how tumour cells manipulate their niche. This abnormal state of myeloma-associated MSCs seems to be induced by multiple myeloma cells 109, 110 , but it is possible that MSCs become abnormal as a pre-myeloma step that could lead to the initiation or propagation of myeloma.
Alterations in the malignant niche
Normal and malignant niches differ in many ways, depending on the type of tumour colonizing the bone and the extent to which the niche has been altered. In general, the accumulation of malignant cells in the bone marrow interferes with feedback signals for normal haemato poiesis, which results in cytopenia 111 .
In osteo lytic niches, which are common with breast cancer and almost exclusively found with multiple myeloma niche colonization, bone formation and resorption activities are uncoupled such that osteoclast activity is increased and osteoblast activity inhibited. In osteo blastic malignant niches, which are common in prostate cancer metastasis, the niche is skewed towards increased numbers and activity of osteoblasts and decreased osteoclast activity. As discussed earlier in this article, tumour-associated MSCs are abnormal 109 and often the immune system is dysregulated, with increased numbers of regulatory T cells and other immune-inhibiting cells, and decreased activity or numbers of effector T cells and other cells that have the capacity to kill tumour cells 112 . Tumour-associated vasculature is often faulty, not only enabling the formation of vessels to feed growing tumours, but also creating leaky neo vasculature, making it more difficult to deliver drugs to tumours, many of which become hypoxic and necrotic in the centre once they have grown large enough 113 . Messenger RNA and microRNA signatures, as well as exosome content and volume from bone marrow stroma, were also found to be abnormal in samples from patients with multiple myeloma 110, 114 . Notch receptor signalling 115 (a critical regulator of HSC fate and differentiation in the bone marrow) and the SDF1-CXCR4 axis are often deviant 116 , extracellular matrix components and ratios are often abnormal 117 , and changes in glycosylation of cell-surface adhesion molecules, such as selectin ligands, integrins and mucins 118 , in cells of the bone marrow are often observed in malignant niches.
Haematopoietic stem cells and tumour cells Parallels in niche homing and colonization
Although the 'vicious cycle' propagates through destructive mechanisms that are absent from healthy HSC-bone marrow interactions, the initial stages of homing to the bone marrow progress similarly for HSCs and tumour cells (FIG. 5) . Many of the same pathways, proteins, and adhesion molecules involved in HSC trafficking to the bone marrow niche are used by metastatic tumour cells, and both cell types show a preference for the highly vascularized metaphysis of the bone 119 . Rather than central marrow, the endosteum seems to be the preferential site for HSCs and tumour cells 120 . Ligand-receptor inter actions of adhesion mol ecules, such as SDF1-CXCR4 (REF. 121 ), integrin α-4-VCAM-1, CD44-osteopontin, and integrin α v β 3 -bone sialoprotein 122 , are important in the homing of HSCs and tumour cells to bone 123 . Calcium receptors also have a role in the niche-homing of HSCs and in the homing and proliferation of cancer cells 123 . PSGL-1 is expressed at high levels in multi ple myeloma cells and its interaction with selectins in the bone marrow enhances adhesion and homing of these cells. Altered glycosylation and expression of sialyl transferases in multiple myeloma cells also affects their adhesion and migration, specifically into the bone marrow 117, 124 . Bone metastasis-specific patterns of messenger RNA and microRNA expression within cancer cells often contain similarities to those of HSCs, providing 85, 97, 125 . On a larger scale, physical features of the bone marrow microenvironment, including acidic pH, high extracellular calcium concentrations, and adjacent sinusoidal blood vessels, also enhance bone colonization by tumour cells (as they do for HSCs) and contribute to the vicious cycle, as described previously 97, 126 . Hypoxia has been implicated both in the induction of tumour quiescence 80 and in egress of tumour cells from the marrow 127 ; these effects, often driven by HIF signalling, are also seen in HSCs [127] [128] [129] . As described above, hypoxia is a characteristic of the bone marrow, but whether the HSC niche (or tumour-homing niche) is always or necessarily hypoxic is still contentious, as HSCs and tumour cells are often found in close proximity to blood vessels 130 . Nonetheless, hypoxia, via HIF-1α, can induce quiescence in HSCs and tumour cells by suppressing mitochondrial oxidative metabolism and promoting anaerobic glyco lysis, which is thought to be the main source of ATP in HSCs 130 . HIF-1α has also been shown to be constitutively expressed by multiple myeloma cells in 35% of patients, independent of actual hypoxic conditions; furthermore, an antisense oligonucleotide inhibiting HIF-1α induced permanent cell-cycle arrest in multiple myeloma cells in preclinical studies 131 , suggesting that targeting HIF-1α in multiple myeloma cells, in either hypoxic or non hypoxic environments, could hold great clinical promise. The bone marrow microenvironment also induces quiescence and drug resistance in tumour cells in the bone marrow, owing in part to metabolic changes such as increased expression of HIF-1α and LDH-A 132 . (FIG. 5) . Bone-metastatic prostate cancer cells have been described as 'parasitizing' the bone marrow niche; via annexin A2 and its corresponding receptor, these cells bind to osteoblasts and become quiescent 133 . Binding of prostate cancer cells to osteoblasts can also induce expression of TANK binding kinase 1 (TBK1), which leads to drug resistance via inhibition of serine/threonine protein kinase mTOR 134 . Prostate cancer cells seem to displace resident HSCs from the niche 135 , and patients with multiple myeloma have been found to have decreased numbers of haemato poietic progenitor cells 136 .
Competition for the niche
These and other studies demonstrate that tumour infiltration inhibits marrow haemato poiesis and can cause anaemia, leukopenia and bone marrow failure by competing with mature haematopoietic cells and HSCs for the same niche 137 . As prostate cancer is one of the only bone-metastatic tumours to cause osteoblastic bone disease, the interactions between prostate cancer and the niche are probably very different from interactions between osteolytic tumours (multiple myeloma and breast cancer) and the niche. The effects of osteoblasts within the HSC niche on the quiescence and drug resistance of dis seminated prostate cancer cells suggests that the induction of more osteoblasts would be advantageous to these tumours. Breast cancer and myeloma cells that hijack the HSC niche would presumably gain the same advantages, yet breast cancer and multiple myeloma cells do not increase osteoblast numbers but rather inhibit osteoblast differentiation; this difference suggests that osteolytic tumours benefit more from tipping the balance towards osteo clastic activity than from inducing more bone marrow niches 138 . The reasons for the development of osteolytic versus osteoblastic lesions, and the differential effects of these lesions on the niche, requires further investigation.
Pre-metastatic niches
Bone loss in malignant or nonmalignant disease is caused by an imbalance between bone formation and bone resorption; increased osteoclast resorption and/or reduced osteoblast bone formation causes pain, hypercalcaemia, fracture, and disrupted haemato poiesis 138 . The bone marrow niche becomes dysfunctional in malignant and nonmalignant bone diseases, and niche dysfunction is also a potential initiator of these diseases -a dilemma that often complicates aetiology and determination of disease origin. Several studies have shown that changing the bone microenvironment before the introduction of cancer cells, using either bortezomib (a bone anabolic agent) in multiple myeloma 139 or breast cancer models 140 or anti-SDF1 pretreatment in a multi ple myeloma model 121 , can make it a less-hospitable environment for tumours.
The concept of a pre-metastatic niche, or an area that is altered to create an environment specific for meta stasis before tumour cells physically arrive, has some provocative support, both in the bone marrow and in other regions 141 (FIG. 6) . By sending out signals to the bone marrow, tumour cells may precondition the niche to facilitate its later colonization. Evidence of this phen omenon has come from a 2015 breast cancer study showing that tumour-secreted protein-lysine 6-oxidase (lysyl oxidase) can cause the formation of pre-metastatic niches in the distant bone marrow by modulating osteo clasts and osteoblasts, and by stimulating osteolysis (hence initiating the vicious cycle), before tumour cells arrive 142 . In another breast cancer study, peripheral blood serum from patients with cancer significantly supported tumour growth and trans-endothelial migration, compared with serum from healthy donors, and contained higher concentrations of PDGF-AB, intercellular adhesion molecule 1 and vascular cell adhesion protein 1, which could aid tumour extravasation, bone resorption and proliferation 143 . Signals from tumour cells can be transmitted in exosomes or other microvesicles or by circulating free DNA to create distant pre-metastatic niches [144] [145] [146] . MSCs have also been found to be recruited to regions of pre-metastatic niches and, through prostaglandin E2 induced by primary tumour-derived VEGF, create a region more susceptible to tumour colonization 147 . Kerr et al. 148 have shown that platelets are pivotal for tumour communication with the bone marrow when creating a pre-metastatic niche, whereas others have found bone-marrow-derived myeloid cells to be crucial in creating pre-metastatic niches in lung 141, 149 . In summary, it seems that tumours probably induce systemic changes and emit systemic signals to hijack, remodel and support tumour-cell colonization of the bone marrow niche 150 .
Niche-directed carcinogenesis
Not only does the bone marrow niche support metastatic tumour cells arriving from distant locations, but it might also have a role in the first tumorigenic event of oncogenesis (FIG. 7) . A 2010 study by Raaijmakers et al. 151 demonstrated that alterations to the normal HSC niche (via deletion of Dicer1 specifically in mouse osteoprogenitors, but not in mature osteoblasts) disrupt the integrity of haematopoiesis and induce myelodysplasia and secondary leukaemia. A subsequent review article by Raaijmakers summarizes much of the work examining how modulations in ancillary cells of the bone marrow could directly cause leukaemogenesis, myelodysplasia and myeloproliferative disorders through ROS formation (inducing DNA damage), by affecting cell-cycle arrest, or via other pathways 90 . These data call into question the dogma that cell-autonomous events lead to initiation of cancer, by suggesting that leukaemias might develop through non-cell autonomous pathways, which might also be true for other haematological malignancies such as multiple myeloma. In summary, the niche might also act as a tumour-enabling milieu by priming or directly initiating tumorigenesis; this concept deserves further investigation.
Recreating the niche experimentally Three-dimensional in vitro models are vital to the correct recapitulation of bone and cancer interactions, as they more accurately capture the physiological interactions and cell-cell signalling within the bone marrow niche than 2D models. Some researchers have used matrigel 152 and other hydrogels as 3D substrates to explore the tumour-supportive effects of MSCs and other properties of the niche, or have expanded 2D cultures on cellulose membranes using perfusion bio reactors to create multi-cell layered, although not porous or trabecular-like, bone mimics 153 . However, 155 , with or without bioreactors or spinner-flasks 156, 157 . The development and use of bioreactors or spinner-flasks for bone tissue engineering, led by the laboratories of Langer, Kaplan and Vunjak-Novakovic among others, often facilitates better nutrient diffusion of biopsies or tissue-engineered samples, allowing for the development of longer-term models with better osteo genic differentiation and mineralization versus soft, hydrogel models, although with potentially increased challenges for imaging or tumour-cell growth [156] [157] [158] [159] . The vascular niche within the bone marrow is another important area that researchers must recapitulate in the bone marrow in vitro 113 . In our models, this was done using RFP-labelled human umbilical vein endothelial cells in co-culture with GFP-labelled MM.1S myeloma cells 110 . Other models include 3D spheroid tri-cultures of osteoblasts, endothelial cells, and prostate cancer cells in microfluidic devices 160 .
Still others have used silk tubes, microfluidic devices, mega karyocyte culture systems, and other types of 3D tissue engineering techniques to model the bone marrow vasculature [161] [162] [163] . Many models also exist to study bone marrow metastasis in vivo. For these models, the researcher must decide what to use in terms of the tumour cell line (or primary cells), the model for bone meta stasis or growth in the bone marrow, the mouse model and/or strain, and the methods to track tumour burden and bone parameters. Examples of commonly used models of metastasis to the host bone morrow are intravenous injection of the myeloma cell line MM.1S 139, 164 , intracardiac injection of the breast cancer cell line MDA-MB-231 (REFS 165, 166) , and intracardiac injection of the prostate cancer cell line PC-3 (REF. 167 ). An advantage of these models is that they recapitulate the latter stages of bone marrow metastasis, including circulation of tumour cells through the bloodstream, rolling and arrest at a distant bone marrow capillary, extravasation across the endothelial lining, colonization of the new microenvironment, proliferation, and hijacking and reprogramming of the bone marrow. As most of these steps are considered rate-limiting, with only a fraction of tumour cells making it through each step, these are typically seen as excellent models for bone metastasis. However, these models do not recapitulate the early stages of bone marrow metastasis, specifically the epithelial-to-mesenchymal cell transition, escape through the basement membrane, and intravasation (the stage where the cancer cell first enters into circulation), which are all necessary steps of distant metastasis for any solid primary tumour.
Another advantage of the injection models described is that they use human, rather than mouse, tumour cells. However, xenograft models require the use of immuno compromised mice, such as Nod/SCID gamma (NSG) or Rag2 -/-mice, and thus cannot accurately capture the roles of the immune system in cancer. Therefore, certain transgenic or syngeneic models (where tumour cells from transgenic mice are directly injected into mice from the same background, to create models of accelerated tumour growth), such as the 5TGM and Vk*Myc multiple myeloma models, are often used to preserve the immune system component of the disease 168, 169 . Importantly, tumour cells often do not colonize the bone marrow after circulatory injection, for interrelated reasons such as tumour clonality, heterogeneity, lack of the traits necessary for bone-homing and engraftment, and entrapment in the lungs, spleen, or other organs. To get tumour cells to grow within the bone marrow, researchers often must use direct orthotopic injections, omitting the steps of extravasation and bone-homing. For example, Medyouf et al. 86 have developed a primary patient co-transplantation model using a xenotransplant (intrafemoral injection) of tumour cells in sublethally irradiated NSG mice. This elegant work demonstrates the ability of myelodysplastic syndrome disease cells to reprogramme progenitors in the bone marrow microenvironment, and illustrates how MSCs facilitate myelodysplastic-cell engraftment -two recurrent themes in the role of MSCs and cancer. Models of direct tumour cell injection into mouse bones (intratibial or intrafemoral 86, 170 ) are advantageous in that they contain real, complete, vascularized, functional bone marrow niches; however, the aggressive injection of a bolus of tumour cells into this niche causes inflammation, bone destruction, and formation of a non-vascularized tumour that has not grown or progressed in response to its bone marrow environment (at least initially). Still, after healing, tumour growth within the bone marrow can be studied and these models have proven important and effective for studying bone-tumour interactions, understanding bone marrow niche destruction, and developing therapeutics 166 . Newer models of bone marrow metastasis use subcutaneously implanted bones, which, depending on the system, allow for several features: easier optical imaging; a more-controlled environment; the existence of multiple identical bone marrow niches within the same mouse; human bone extracellular matrix and cellular constituents; and a potentially less-inflammatory bone marrow niche (versus direct injection of tumour cells into bone). These models variously use implanted human bone (fetal bone or adult bone from hip replacement surgery; known as a SCID-hu model) 171 , rabbit bone (SCID-rab model) 172 , or mouse bone (SCID-mu model) 121 . Tissue-engineered bone (TE-bone) models from silk scaffolds 114, [173] [174] [175] , calcium phosphate scaffolds 155 , or other biomaterials are also now being utilized as more controllable, reproducible bone-marrow-niche models to investigate the contributions of bone marrow stroma to tumour engraftment or metastasis. For example, one silk-scaffold model utilizes bone marrow stromal cells that are seeded onto silk scaffolds and differentiated into TE-bone that can then be used to study breast cancer metastasis 175 . In this way, different cellular or biochemical components of the bone-marrow microenvironment can be specifically studied for their individual contributions to bone-marrow metastasis. Effects on tumour growth can also be studied by directly injecting tumour cells into TE-bone after implantation or by co-seeding tumour cells into TE-bone cultures before implantation. Paton-Hough et al. 166 have comprehensively reviewed current in vivo myeloma models, and the drawbacks, advantages, and caveats of each.
Challenges remain in fully recapitulating the niche in vivo and in vitro, in part because of the dynamic nature of the microenvironment. As noted, hypoxia is a critical element of the niche, not only for maintaining stemness, but also for inducing glycolytic pathways that maintain the vitality of the niche. Hence, the bioenergetic pathways of the niche must be faithfully maintained, which requires specific nutrient and oxygen concentrations in the media. Similarly the cell-cell interactions described above, whether related to malignant-cell communication with stromal elements or MSC-HSC exchanges, have unique requirements and stages of differentiation that are difficult to restore completely in an artificial environment. Notwithstanding these obstacles, accurate redefinition of the niche in vitro will provide significant insights and important platforms for testing new therapies.
Translational implications
Disorders of the bone marrow niche are manifest in several disorders, including myelodysplastic syndromes, myeloproliferative disorders, aplastic anaemias, leukaemias, metastatic diseases, polycythemia vera, and thrombocytosis. Skeletal disorders, including some primary and secondary osteoporotic syndromes, can be considered disorders of the niche. Postmenopausal osteoporosis can be heterogeneous in terms of its aetiology relative to the bone marrow niche. In some women, the underlying disorder is an impairment in bone formation, which may be attributable to defective MSC recruitment. On the other hand, some women have increased bone resorption which is related to higher RANKL production and may be due to a combination of greater number of CD4 + T cells and/or a suppression of regulatory T cells 176 . Thus, drugs for treating osteoporosis that target osteoblasts or their progenitors could have substantial effects on HSCs. The most frequently used 'anabolic' agent is PTH , which enhances osteoblast differentiation and builds bone mass 177 . PTH also induces HSC differentiation and can enhance mature peripheral erythroid and myeloid elements 24 . On the other hand, agents such as bortezomib, a proteasome inhibitor used to treat myeloma, may also induce MSC differentiation into mature osteoblasts, increasing bone mass and reducing myeloma progression in the marrow 139, 178 . As the niche becomes more completely characterized in vivo and recapitulated in vitro, better therapies for chronic haema tologic disorders, malignancies, and skeletal diseases will undoubtedly emerge.
One offshoot of work to define the bone marrow niche is the therapeutic use of MSCs. Although ~400 trials have been conducted using MSCs to treat a wide range of disorders, neither the FDA nor the European Medicines Agency has yet approved any MSC therapy 2 . Thus, over the past two decades, despite a plethora of publications and the promise for clinical applications, the role of MSCs in the treatment of heart disease, Alzheimer disease, diabetes mellitus or osteoporosis remains to be determined.
Conclusions
In summary, the bone marrow niche provides a home for HSCs and MSCs. The niche supports the integration of two major organ systems, the skeleton and the marrow. Even subtle alterations in the niche, whether biochemical or cytological, can lead to chronic diseases and could affect the host response to, or directly initiate, malignancies. Approaches using MSCs to treat common disorders are still experimental yet are relevant to the design of therapeutics that target the niche. As such, a more-complete understanding of the biology of this unique microenvironment within the bone marrow must, without doubt, continue to be a major research priority.
